Literature DB >> 35355731

Safety Profile of Antipsychotic Drugs: Analysis Based on a Provincial Spontaneous Reporting Systems Database.

Kangyuan Guo1, Zhanchun Feng1, Shanquan Chen2, Ziqi Yan1, Zhiming Jiao1, Da Feng3.   

Abstract

Introduction: Antipsychotic drugs are the main therapy for schizophrenia and have been widely used in mental disorder fields. However, the research on the safety of antipsychotic drugs in the real-world is rare. The purpose of this research is to evaluate the safety of antipsychotic drugs based on real-world data.
Methods: ADR reports collected by the Henan Adverse Drug Reaction Monitoring Center from 2016 to 2020 were analyzed. We described the safety of antipsychotic drugs by descriptive analysis and four signal mining methods. Meanwhile, the risk factors for serious adverse reactions of antipsychotics were identified.
Results: A total of 3363 ADR reports related to antipsychotics were included. We found that the number of adverse drug reaction reports and the proportion of serious adverse reactions have increased year by year from 2016 to 2020. Most adverse drug reactions occurred within 3 months after taking the medicine. The symptoms caused by typical antipsychotics and atypical antipsychotics were different and dyskinesia was more common in typical antipsychotics. Most patients improved or recovered after treatment or intervention while only one patient had sequelae. Low-level hospitals, psychiatric hospitals, youth, and old age could increase the risk of serious adverse reactions. Four off-label signals were found through signal mining, including amisulpride-pollakiuria, ziprasidone-dyspnoea, quetiapine-urinary incontinence, olanzapine-hepatic function abnormal.
Conclusion: We found that most ADRs occurred within 3 months after taking the medicine, so close observation was required for patients during the first 3 months of treatment. The ADRs of antipsychotics involved multiple organ-system damages but were not serious. It might be recommended to take alternative drugs after a serious ADR occurred. The symptoms caused by typical APDs and atypical APDs were different. For patients with typical APDs, dyskinesia was more common and should be given special attention. Statistics showed that low-level hospitals, psychiatric hospitals, youth, and old age were risk factors for serious ADRs. The four off-label signals obtained by signal mining should be paid special attention, including amisulpride-pollakiuria, ziprasidone-dyspnoea, quetiapine-urinary incontinence, and olanzapine-hepatic function abnormal.
Copyright © 2022 Guo, Feng, Chen, Yan, Jiao and Feng.

Entities:  

Keywords:  adverse drug reaction; antipsychotics; pharmacovigilance; risk factor; schizophrenia; signal mining; spontaneous reporting system

Year:  2022        PMID: 35355731      PMCID: PMC8959618          DOI: 10.3389/fphar.2022.848472

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  40 in total

1.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.

Authors:  S J Evans; P C Waller; S Davis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2001 Oct-Nov       Impact factor: 2.890

2.  Urinary incontinence associated with amisulpride.

Authors:  Dattatreya Mendhekar; Deep Lohia
Journal:  World J Biol Psychiatry       Date:  2009       Impact factor: 4.132

3.  A Bayesian neural network method for adverse drug reaction signal generation.

Authors:  A Bate; M Lindquist; I R Edwards; S Olsson; R Orre; A Lansner; R M De Freitas
Journal:  Eur J Clin Pharmacol       Date:  1998-06       Impact factor: 2.953

4.  Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making.

Authors:  Jessica M Franklin; Robert J Glynn; David Martin; Sebastian Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2019-02-25       Impact factor: 6.875

5.  Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia.

Authors:  Wolfgang Gaebel; Mathias Riesbeck; Wolfgang Wölwer; Ansgar Klimke; Matthias Eickhoff; Martina von Wilmsdorff; Matthias Lemke; Isabella Heuser; Wolfgang Maier; Wolfgang Huff; Andrea Schmitt; Heinrich Sauer; Michael Riedel; Stefan Klingberg; Wolfgang Köpcke; Christian Ohmann; Hans-Jürgen Möller
Journal:  J Clin Psychiatry       Date:  2010-06-29       Impact factor: 4.384

Review 6.  Novel data-mining methodologies for adverse drug event discovery and analysis.

Authors:  R Harpaz; W DuMouchel; N H Shah; D Madigan; P Ryan; C Friedman
Journal:  Clin Pharmacol Ther       Date:  2012-06       Impact factor: 6.875

Review 7.  Intermittent drug techniques for schizophrenia.

Authors:  Stephanie Sampson; Kajal Joshi; Mouhamad Mansour; Clive E Adams
Journal:  Schizophr Bull       Date:  2013-07-16       Impact factor: 9.306

Review 8.  Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016.

Authors:  Fiona J Charlson; Alize J Ferrari; Damian F Santomauro; Sandra Diminic; Emily Stockings; James G Scott; John J McGrath; Harvey A Whiteford
Journal:  Schizophr Bull       Date:  2018-10-17       Impact factor: 9.306

Review 9.  A Systematic Review and Pooled, Patient-Level Analysis of Predictors of Mortality in Neuroleptic Malignant Syndrome.

Authors:  Daniel Guinart; Fuminari Misawa; Jose M Rubio-Lorente; Justin Pereira; Renato de Filippis; Chiara Gastaldon; John M Kane; Christoph U Correll
Journal:  Acta Psychiatr Scand       Date:  2021-08-06       Impact factor: 6.392

10.  Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Authors: 
Journal:  Lancet       Date:  2017-09-16       Impact factor: 79.321

View more
  1 in total

1.  Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia.

Authors:  Olga Yu Fedorenko; Diana Z Paderina; Elena G Kornetova; Evgeniya G Poltavskaya; Ivan V Pozhidaev; Anastasiia A Goncharova; Maxim B Freidin; Anna V Bocharova; Nikolay A Bokhan; Anton J M Loonen; Svetlana A Ivanova
Journal:  Diagnostics (Basel)       Date:  2022-06-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.